PEGASCY

Pegascy focuses on the repositioning of shelved molecules in clinical stage. After an initial success with Imgatuzab GA201 (sold to Centessa Pharmaceutical (Nasdaq:CNTA) in 2021), we are about to launch PegaTwo: a Phase 2 Clinical Trial with Istiratumab (MM141), our own Bispecific Antibody focusing Pediatric and rare gynecological Cancers. We have 2 additional molecules in the pipeline (including an ADC that has demonstrated an impressive clinical efficacy in tumors expressing CEACAM5) which will enter Phase 2 clinical trials in early 2026. More generally, The Pegascy initiative as defined by its founders: “There might be an opportunity to identify recently abandoned molecules to be refocused for a good price after their Pre-Clinical tests if we get together a selected “best in class” college of Researchers which will be able to determine applications to new indications for patients with no effective treatment as of today and, also, who will design new smart Clinical Trial applicable under their responsibility”. In other words, there is a real medical opportunity in revisiting discarded cancer drugs rather than starting new ones from scratch. It needs sharper, sharper, efficient and effective ways to unlock what’s already there.